SeCOND AMENDMENT TO OPTION and License AgreementOption and License Agreement • February 15th, 2022 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
This SECOND AMENDMENT TO OPTION AND LICENSE AGREEMENT (“Second Amendment”) is entered into as of December 17, 2021 (“Second Amendment Effective Date”) by and between REGENXBIO Inc., a corporation organized under the laws of the State of Delaware, with offices at 9804 Medical Center Drive, Rockville, MD 20850 (“Licensor”), and Ultragenyx Pharmaceutical Inc., a corporation organized under the laws of the State of Delaware, with offices at 840 Memorial Drive, Cambridge, MA 02139 (“Licensee”). Licensor and Licensee are hereinafter referred to individually as a “Party” and collectively as the “Parties.”
AMENDMENT NO. 11 TO COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • February 15th, 2022 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
This Amendment No. 11 to the Collaboration and License Agreement, (“Amendment”) is made and entered into by and between Kyowa Kirin Co., Ltd. (formerly, Kyowa Hakko Kirin Co., Ltd.), a company organized and existing under the laws of Japan, with an address at 1-9-2 Otemachi, Chiyoda-ku, Tokyo, 100-0004, Japan ("KKC’') and Ultragenyx Pharmaceutical Inc., a company organized and existing under the laws of the State of Delaware, with an address at 60 Leveroni Court, Novato, California 94949, USA ("UGNX'' ).
